Wyoming Drug Utilization Review (WY-DUR)

School of Pharmacy | College of Health Sciences

News

Preferred Drug List (PDL)

The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit www.wymedicaid.org.

The Draft 2018 PDL, effective January 1, 2018, is available for review.

Public Comment at Meetings:

A new policy for public comment at meetings is effective December 2, 2012.

PhRMA Guidelines and PhRMA Comment Request Form (updated November 5, 2015)

Public Guidelines and Public Comment Request Form (updated November 5, 2015)

Proposed Criteria

The following prior authorization criteria were approved at the August 9, 2018 P & T Committee meeting.

Opiate medications will be limited to a 7-day supply for opiate naïve patients only, defined as anyone who has not had a claim for an opiate product in the previous 45 days.

Jynarque, Samsca, Crysvita, and Tavalisse will be limited to indication. Rhopressa, cyclosporine in Klarity, and Osmolex ER and isotretinoin agents will be added to the preferred drug list following cost analysis by the Department of Health.

Aimovig will require a three-month trial and failure of three generic prophylactic agents from different classes including divalproex, tricyclic antidepressants, beta blockers and topiramate. Botox is not included in required trials.

Long-acting injectable antipsychotics will be limited to 150% of labeled maximum dose immediately. Additional information will be provided regarding the appropriateness of the 150% level for oral and injectable products at the November meeting.

Comments may be sent by email to alewis13@uwyo.edu or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY 82071. Comments should be received prior to October 1, 2018.